Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...

A bankruptcy judge approved the sale of genetics company 23andMe to a non-profit led by co-founder and former CEO Anne Wojcicki, according to a June 27 filing in the bankruptcy docket. TTAM Research ...

Regeneron Pharmaceuticals announced on Monday that it will acquire "substantially all" of genetic testing company 23andMe's assets. The pharmaceutical company said it won the court-supervised auction ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth provider ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, and its trove of genetic data. Her $305 million offer topped the previous ...

A U.S. bankruptcy judge has cleared 23andMe’s $305 million sale to TTAM Research, a nonprofit led by co-founder Anne Wojcicki, rejecting California’s attempt to delay the deal over privacy concerns.

Bankrupt 23andMe is facing a lawsuit over its plans to sell customer genetic information. Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S.